<DOC>
	<DOCNO>NCT01192633</DOCNO>
	<brief_summary>The primary objective study evaluate PFS gemcitabine , vincristine cisplatin second line therapy patient sarcoma . 40 patient treat study .</brief_summary>
	<brief_title>Gemcitabine , Vincristine Cisplatin Second Line Combination Therapy Patients With Sarcoma</brief_title>
	<detailed_description />
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>Give write informed consent prior study , understand patient right withdraw study time without prejudice Be female male ≥18 ≤75 year age Be ambulatory ECOG performance status ≤1 Have histological confirm sarcoma Locally advance metastatic sarcoma receive firstline chemotherapy . Have least one target lesion accord RECIST criterion . Pregnant lactate woman patient receive chemotherapy drug include gemcitabine , vincristine cisplatin Chemotherapy within four week precede treatment start ECOG ≥ 2 Radiotherapy axial skeleton within 4 week precede study treatment start insufficient recovery effect prior radiotherapy Participation investigational drug study within 4 week precede treatment start History another malignancy within last five year except cure basal cell carcinoma skin carcinoma insitu uterine cervix .Abnormal laboratory value : hemoglobin &lt; 8 . 0g/dl , neutrophil &lt; 1.5×109/L , platelet &lt; 100×109/L . serum creatine &gt; upper limit normal ( ULN ) serum bilirubin &gt; ULN alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) &gt; 5×ULN alkaline phosphatase ( AKP ) &gt; 5×ULN Serious uncontrolled intercurrence infection Life expectancy le 3 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>Sarcoma</keyword>
	<keyword>gemcitabine</keyword>
	<keyword>vincristine</keyword>
	<keyword>cisplatin</keyword>
	<keyword>chemotherapy</keyword>
</DOC>